Home > Research Areas
Cat. No. Product name CAS No.
DC10456 STF-62247 Featured

STF-62247 is a small molecule agonist that induces autophagy and selectively causes lethality in renal cell carcinoma (RCC) cells that have lost the von Hippel-Lindau (VHL) tumor suppressor activity (IC50 = 625 nM).

315702-99-9
DCAPI1445 strontium ranelate

Strontium Ranelate is a bone metabolism modulator that inhibits bone resorption while maintaining bone formation. Commonly used as an antiosteoporotic.

135459-87-9
DC7302 SU14813 Featured

SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).

627908-92-3
DC5079 Orantinib (TSU-68) Featured

SU6668 has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR.

252916-29-3
DC6906 Aprepitant (MK-0869, L-754030) Featured

Substance P antagonists (SPA).

170729-80-3
DC10581 Succinobucol(AGI 1067) Featured

Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.

216167-82-7
DC9732 Sufugolix(TAK-013) Featured

Sufugolix(TAK-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively).

308831-61-0
DC3145 Sunitinib base Featured

Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

557795-19-4
DCAPI1388 Suplatast tosylate

Suplatast tosylate

94055-76-2
DC10733 Sutezolid (PNU-100480) Featured

Sutezolid (PNU-100480) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis.

168828-58-8
DC5017 Suvorexant Featured

Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.

1030377-33-3
DC8852 SW-044248 Featured

SW-044248 is a Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.

522650-83-5
DC8308 SYM2206

SYM2206 is a novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ).

173952-44-8
DC5105 Favipiravir (T-705) Featured

T 705(Favipiravir) is a RNA-directed RNA polymerase NS5B inhibitor.T 705(Favipiravir) is useful for Antiviral agents.

259793-96-9
DC9842 T0901317 Featured

T0901317 is a potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-α and LXR-β respectively).

293754-55-9
DC8024 T-5224 Featured

T-5224 is a selective inhibitor of c-Fos/activator protein (AP)-1, attenuates lipopolysaccharide-induced liver injury in mice.

530141-72-1
DC5901 Tadalafil Featured

Tadalafil is a potent and selective inhibitor of Phosphodiesterase-5 (PDE5) This compound prevents the breakdown of phosphodiesterases, many of which are used as secondary messengers. By preventing the breakdown of these messenger molecules, tadalafil can

171596-29-5
DC7945 TAK-063 Featured

TAK-063 is a highly potent, selective and orally active PDE10A inhibitor with IC50 of 0.30 nM; >15000-fold selectivity over other PDEs.

1238697-26-1
DC11208 TAK-071 Featured

TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM.

1820812-16-5
DC9311 Serabelisib(TAK-117,INK1117,MLN1117) Featured

TAK-117(INK1117,MLN1117) is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity.

1268454-23-4
DC11633 TAK-243 Featured

TAK-243 (MLN-7243, AOB87172) is a small-molecule, cell-permeable inhibitor of ubiquitin-activating enzyme E1 (UAE1).

1450833-55-2
DC7306 TAK-438 Featured

TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion.

1260141-27-2
Page 50 / Total 59 FirstPrevNextLastGoto